Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC

Similar Items

• Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC
  od: Sanborn, Rachel, i dr.
  Izdano: (2015)
• Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory t cells
  od: Ye, Wei, i dr.
  Izdano: (2014)
• DPV-001 an autophagosome-enriched cancer vaccine in phase II clinical trials contains 25 putative cancer antigens, DAMPS, HSPS and agonists for TLR 2, 3, 4, 7 and 9
  od: Hilton, Traci L, i dr.
  Izdano: (2013)
• Characterizing the immunoprofile and endogenous immune response to squamous cell carcinomas of the head and neck to guide development of effective immunotherapy strategies
  od: Moudgil, Tarsem, i dr.
  Izdano: (2014)
• Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIB
  od: Wilkinson, Fiona L., i dr.
  Izdano: (2012)